Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial

NCT07715565 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

66

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma (Kidney Cancer)
Immunotherapy
Molecular Targeted Therapy

Interventions

DRUG: Ipilimumab Injection
DRUG: Sintilimab injection
DRUG: Lenvatinib

Sponsor

West China Hospital